BIOSIG TECHNOLOGIES (OTCMKTS:BSGM)’s Trend Up, Especially After Decreased Shorts

September 17, 2017 - By Peter Erickson

The stock of BIOSIG TECHNOLOGIES (OTCMKTS:BSGM) registered a decrease of 3.74% in short interest. BSGM’s total short interest was 18,000 shares in September as published by FINRA. Its down 3.74% from 18,700 shares, reported previously. With 31,700 shares average volume, it will take short sellers 1 days to cover their BSGM’s short positions.

The stock increased 1.10% or $0.01 on September 15, reaching $1.26. About 1,959 shares traded. BioSig Technologies Inc (OTCMKTS:BSGM) has 0.00% since September 17, 2016 and is . It has underperformed by 16.70% the S&P500.

BioSig Technologies, Inc. is a development-stage medical device company. The company has market cap of $32.77 million. The Firm is developing a technology platform to manage noise and artifacts from cardiac recordings during electrophysiology studies and ablation. It currently has negative earnings. It is engaged in developing the Precise Uninterrupted Real-time evaluation of Electrograms electro-pneumatic (EP) System.

More notable recent BioSig Technologies Inc (OTCMKTS:BSGM) news were published by: Tcbmag.com which released: “BioSig Technologies Issues Big Warrant Position to Mayo Clinic Ventures” on May 31, 2017, also Globenewswire.com with their article: “BioSig Technologies Sponsors The 11th International Symposium on Ventricular …” published on September 26, 2016, Marketwired.com published: “BioSig Technologies Announces the Appointment of Jerome B. Zeldis to Its Board …” on April 09, 2015. More interesting news about BioSig Technologies Inc (OTCMKTS:BSGM) were released by: Globenewswire.com and their article: “BioSig Technologies Provides Shareholder Update” published on April 25, 2017 as well as Globenewswire.com‘s news article titled: “BioSig Technologies to Present at SeeThruEquity 3rd Annual Innovations …” with publication date: February 21, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.